Mozifor (Plerixafor) 24 mg / 1.2 ml
Mozifor is a hematopoietic stem cell mobilizer. Active ingredient: Plerixafor (24 mg / 1.2 ml).
Manufacturer: Hetero Healthcare (India). Generic equivalent of Mozobil.
Mechanism of Action:
Plerixafor is a reversible inhibitor of the CXCR4 chemokine receptor. It blocks the interaction between CXCR4 and SDF-1alpha, which "anchors" stem cells in the bone marrow. By breaking this bond, Mozifor releases stem cells into the bloodstream, allowing them to be collected for transplantation.
✅ Key Benefit: Increases the yield of CD34+ stem cells in patients who fail to mobilize enough cells with G-CSF alone.
Indicated in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with:
- Non-Hodgkin's Lymphoma (NHL).
- Multiple Myeloma (MM).
⚠️ For Subcutaneous (SC) Injection Only.
Administration Timing:
- 💉 Administered approximately 6 to 11 hours prior to the initiation of each apheresis (cell collection) session.
- Treatment usually lasts for 2 to 4 consecutive days.
Dosing:
- Body weight ≤ 83 kg: Fixed dose of 20 mg.
- Body weight > 83 kg: 0.24 mg/kg actual body weight.
- Leukemia: Should not be used in leukemia patients due to the risk of mobilizing leukemic cells.
- Pregnancy (Teratogenic effects).
- Breastfeeding.
- Hypersensitivity to Plerixafor.
Common adverse reactions include:
- Gastrointestinal: Diarrhea, nausea, vomiting, abdominal pain.
- Injection Site Reactions: Erythema, swelling, bruising, and pain.
- Systemic: Fatigue, headache, dizziness.
- Musculoskeletal pain (bone pain).
What Customers Say
No reviews yet
Your review can be the first!